Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 3
2018 2
2019 1
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.
Perdrix A, Najem A, Saussez S, Awada A, Journe F, Ghanem G, Krayem M. Perdrix A, et al. Among authors: Najem A. Cancers (Basel). 2017 Dec 16;9(12):172. doi: 10.3390/cancers9120172. Cancers (Basel). 2017. PMID: 29258181 Free PMC article. Review.
Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis.
Soumoy L, Schepkens C, Krayem M, Najem A, Tagliatti V, Ghanem GE, Saussez S, Colet JM, Journe F. Soumoy L, et al. Among authors: Najem A. Cancers (Basel). 2020 May 22;12(5):1323. doi: 10.3390/cancers12051323. Cancers (Basel). 2020. PMID: 32455924 Free PMC article.
Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma.
Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L, de Wijn R, Hilhorst R, Ruijtenbeek R, Sabbah M, Kerger J, Awada A, Journe F, Ghanem GE. Krayem M, et al. Among authors: Najem A. Cancers (Basel). 2020 Feb 22;12(2):512. doi: 10.3390/cancers12020512. Cancers (Basel). 2020. PMID: 32098410 Free PMC article.
Feedback